TKPHF (TKPHF) Stock Price & Analysis
TKPHF (TKPHF) rose 6.99% to USD 32.6 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
TKPHF last closed at USD 30.47; the session ranged USD 32.6–32.6 on volume of 200 shares. Market capitalization is $51.50B, with a 52-week range of USD 26.33–39.2 (PNK). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 32.6 |
|---|---|
| Change | ▲ 6.99% (up) |
| Previous Close | USD 30.47 |
| Open | USD 32.6 |
| Day Range | USD 32.6 – 32.6 |
| 52-Week Range | USD 26.33 – 39.2 |
| Volume | 200 shares |
| Market Cap | $51.50B |
| Exchange | PNK |
Technical Analysis (TKPHF)
Nexqual's technical model rates TKPHF "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.6 (oversold) |
| vs SMA50 | Below (USD 33.01) |
| MACD | -0.75 (negative) |
Analyst Ratings (TKPHF)
Wall Street analysts rate TKPHF "None", per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | None |
|---|
Earnings (TKPHF)
| Next Earnings Date | 2026-07-30 |
|---|---|
| Revenue Estimate | $1.16T |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (TKPHF)
| Total Revenue | $4.51T |
|---|---|
| Revenue Growth (YoY) | +3.90% |
| Gross Margin | +65.12% |
| Operating Margin | +3.09% |
| Profit Margin | +4.26% |
| ROE | +2.61% |
| Debt / Equity | 70.14 |
| Current Ratio | 1.27 |
| Total Cash | $595.05B |
| Total Debt | $5.45T |
| Free Cash Flow | $356.63B |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (TKPHF)
Nexqual rates TKPHF's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Strong — Revenue +676% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 65%, operating 3% |
| Balance Sheet | Solid — $595.1B cash vs $5.45T debt |
| Cash Flow | Solid — FCF $356.6B, 8% margin |
| Efficiency | Weak — ROE 3%, ROA 2.6% |
Ownership (TKPHF)
| Insider Ownership | +0.03% |
|---|---|
| Institutional Ownership | +50.87% |
| Shares Outstanding | 1.58B |
| Float | 1.58B |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (TKPHF)
TKPHF is led by Christophe P. Weber (age 59), President, CEO & Representative Director, per Nexqual as of June 10, 2026 at 02:23 UTC.
| President, CEO & Representative Director | Christophe P. Weber (age 59) |
|---|---|
| CFO & Director | Milano Furuta (age 47) |
| President of Research & Development and Representative Director | Andrew S. Plump (age 60) |
| Chief Operating Officer | Michael Fox |
| Senior Vice President of Corporate Finance & Controlling Department | Iwaaki Taniguchi |
Major Backers & Investors (TKPHF)
Notable institutional backers of TKPHF include Capital Group, Goldman Sachs, Capital Income Builder, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 0.87% |
| Goldman Sachs | 0.64% |
| Capital Income Builder | 0.37% |
| Fidelity | 0.37% |
| INVESTMENT CO OF AMERICA | 0.33% |
| Pacer Advisors, Inc. | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.39% |
| BlackRock | 1.47% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 14.96 | ▼ 2.09% |
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 22.85 | ▼ 0.91% |
| ALPMF | Astellas Pharma, Inc. | USD 14.26 | ▲ 0.42% |
| MKKGY | Merck KGaA | USD 32 | ▲ 2.11% |
| BAYZF | Bayer A.G. | USD 41.27 | ▼ 0.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.